

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on 24 January 2001.

By: [Signature]  
Printed: Katherine Stofer



Docket No.: PF-0346-1 DIV

1644  
#9  
**RECEIVED**

FEB - 1 2001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Hillman et al.

TECH CENTER 1600...

Title: T-CELL RECEPTOR PROTEIN (AS AMENDED)

Serial No.: 09/405,940

Filing Date: September 27, 1999

Examiner: Ewoldt, G.

Group Art Unit: 1644

Commissioner for Patents  
Washington, D.C. 20231

**AMENDMENT TRANSMITTAL FEE SHEET**

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Postcard;
2. Response Transmittal (1 pg., in duplicate);
3. Response to Office Action (8 pp., in duplicate);
4. Copy of executed Declaration and Power of Attorney as originally signed (3 pp); and
5. Exhibits 1, 2, 3, 4, 5, and 6.

The fee has been calculated as shown below.

Claims	Claims After Amendment	-	Claims Previously Paid For	=	Present Extra	Other Than Small Entity Rate Fee	Additional Fee(s)
Total Claims	6	-	20	=	0	\$18	\$ 0
Indep. Claims	3	-	3	=	0	\$80	\$ 0
___ First Presentation of Multiple Dependent Claim						+\$270	\$ 0

**TOTAL** \$ 0

- ☒ No additional fee is required.  
\_\_\_ Fee for Request for Extension of Time (\_\_\_ months) \$ \_\_\_  
\_\_\_ Please charge Deposit Account No. 09-0108 the amount of \$ \_\_\_

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: January 24, 2001

David G. Streeter


David G. Streeter, Ph.D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 849-8886

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on 24 January 2001.

By:   
Printed: Katherine Stofer



Docket No.: PF-0346-1 DIX

9/D  
C. E.  
2/3/01  
**RECEIVED**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

FEB - 1 2001

In re Application of: Hillman et al.

**TECH CENTER 1800/2900**

Title: T-CELL RECEPTOR PROTEIN (AS AMENDED)

Serial No.: 09/405,940

Filing Date: September 27, 1999

Examiner: Ewoldt, G.

Group Art Unit: 1644

Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO OFFICE ACTION**

Sir:

In response to the Office Action dated October 24, 2000 (Paper No. 8), Applicants request reconsideration of the above-referenced patent application in view of the following amendments and remarks.

IN THE SPECIFICATION

Please amend the specification as follows:

At page 1, line 1, please insert "This application is a divisional application of U.S. Application Serial No. 08/897,097, filed July 18, 1997, now U.S. Patent No. 6,054,292".

IN THE CLAIMS

Please amend claims 1, 2 and 13 as indicated below.

1. (Twice Amended) A [substantially] purified T-cell receptor beta protein comprising the amino acid sequence of SEQ ID NO: 1[, an allelic variant thereof, or a fragment thereof].

2. (Once Amended) A variant of T-cell receptor beta-like protein having at least 90% amino acid identity to SEQ ID NO: 1 and which retains IL-2 inducing activity [at least one functional